FOXP3 and amyotrophic lateral sclerosis: The safety and potential efficacy of allogeneic cord-blood-derived FOXP3+ Treg cells are also being evaluated in an ongoing clinical trial involving six patients with amyotrophic lateral sclerosis (ALS) without HLA matching (NCT05695521).